On January 6, 2020, Dyadic International, Inc. (the “Company”) provided an update on its recent business developments and scientific results in the fourth quarter of 2019.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

DYADIC INTERNATIONAL INC Exhibit
EX-99 2 ex991dyadicyeupdatepr.htm EX-99.1 Document Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019•Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study•New Collaboration Agreement with Top Ten Pharmaceutical Company •Expanded Research Relationship with Leading Pharmaceutical Company•IIBR Collaboration Achieved Expression of Fc-fusion Enzyme to Counter Biological Attacks •Glycoengineering Data Reinforces Company’s Accelerated Glyco Strategy •Two New Patent Applications JUPITER,…
To view the full exhibit click here

About Dyadic International, Inc. (OTCMKTS:DYAI)

Dyadic International, Inc. (Dyadic) is a holding company. The Company is a global biotechnology company with operations in the United States and the Netherlands. Dyadic uses its technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzymes industries. Its activities relating to selling enzymes focuses on utilizing its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 (Myceliopthora thermophila) fungal strains in the production of its industrial enzymes. Dyadic manufactures, purchases, and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles and biofuels industries. It is focused on biofuels and bio-based chemicals, biopharmaceuticals and industrial products.